DCP is also useful as a marker in HCC diagnostics in combination with other markers such as AFP and AFP-L3 [46], in monitoring the treatment with transarterial chemotherapy [47], and also for choosing the therapy itself, since DCP antagonizes the apoptotic activity of gefitinib, thus leading either to a lack or to a poor response to the treatment [48]. Here, ACE is linked to hepatocellular carcinoma.